Botulinum toxin type A (BTA) impact in Rehabilitation - patient perspective in a medium and long term

Detalhes bibliográficos
Autor(a) principal: Gouveia, Suzana; Interna de MFR do Hospital de Santa Maria, Lisboa, Portugal
Data de Publicação: 2013
Outros Autores: Afonso, Carla; Interna de MFR do Centro de Medicina de Reabilitação de Alcoitão, Portugal, Jacinto, Jorge; Assistente Hospitalar de MFR do Centro de Medicina de Reabilitação de Alcoitão, Portugal
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.25759/spmfr.55
Resumo: Botulinum toxin type A (BTA) has been used in our institution since 2001 in a growing number of patients, which lead to the creation of a specific spasticity treatment clinic. We have 370 patients up to October 2007, which account for a total of 731 treatment sessions. We aimed to evaluate the impact of this treatment on the perspective of the patients treated during 2006, and to make a comparative analysis of the results obtained with those of a previous study that we published in 2004. We selected the patients treated in 2006, who had started treatment with BTA for more than 1 year and had had since more than 1 treatment session (n=62). We made a telephone enquiry, consisting of 7 multiple choice questions, and we obtained 54 answers to the hole enquiry. The results were statistically analysed. We found that spasticity was of cerebral aetiology in 100% of cases , and hemiparesis was the most frequent clinical situation (81,5%). The patients’/carers’ aims were: to reduce spasticity (70,4%), to be able to walk better (50%), and to reduce pain (35,2%). The result was satisfying in 90,8% of cases, the local and regional effects predominated (87%) and side effects were very scarse (5,7%). This treatment was considered very relevant for the rehabilitation process (98,1%), which translated in clear motivation for continuing with the treatment in 96,3% of cases. In comparison with the previous study from 2003, there is a statistically significant difference concerning the aims for starting the treatment, which used to focus more on improving posture and facilitate activities of daily living, apart from controlling spasticity. BTA continues to be recognized by patients/carers as an effective, safe and very relevant treatment within the rehabilitation process.
id RCAP_00dbd5e3414dfc19e97ed849f03a6766
oai_identifier_str oai:ojs.spmfrjournal.org:article/55
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Botulinum toxin type A (BTA) impact in Rehabilitation - patient perspective in a medium and long termImpacto da Toxina Botulínica tipo A na Reabilitação - perspectiva do doente / cuidador a médio e longo prazoBotulinum toxin type A (BTA) has been used in our institution since 2001 in a growing number of patients, which lead to the creation of a specific spasticity treatment clinic. We have 370 patients up to October 2007, which account for a total of 731 treatment sessions. We aimed to evaluate the impact of this treatment on the perspective of the patients treated during 2006, and to make a comparative analysis of the results obtained with those of a previous study that we published in 2004. We selected the patients treated in 2006, who had started treatment with BTA for more than 1 year and had had since more than 1 treatment session (n=62). We made a telephone enquiry, consisting of 7 multiple choice questions, and we obtained 54 answers to the hole enquiry. The results were statistically analysed. We found that spasticity was of cerebral aetiology in 100% of cases , and hemiparesis was the most frequent clinical situation (81,5%). The patients’/carers’ aims were: to reduce spasticity (70,4%), to be able to walk better (50%), and to reduce pain (35,2%). The result was satisfying in 90,8% of cases, the local and regional effects predominated (87%) and side effects were very scarse (5,7%). This treatment was considered very relevant for the rehabilitation process (98,1%), which translated in clear motivation for continuing with the treatment in 96,3% of cases. In comparison with the previous study from 2003, there is a statistically significant difference concerning the aims for starting the treatment, which used to focus more on improving posture and facilitate activities of daily living, apart from controlling spasticity. BTA continues to be recognized by patients/carers as an effective, safe and very relevant treatment within the rehabilitation process.A toxina botulínica tipo A é utilizada na nossa instituição desde 2001 num número crescente de doentes, o que se traduziu na criação de uma consulta específica, com 370 doentes inscritos até Outubro de 2007, correspondendo a 731 sessões de tratamento. Pretende-se avaliar o impacto deste tratamento nos doentes tratados no ano de 2006 e efectuar uma análise comparativa dos resultados com os de um estudo prévio, que publicámos em 2004. Seleccionados os doentes tratados com toxina botulínica no ano 2006, que haviam então iniciado tratamento há mais de 1 ano e efectuado mais de uma sessão (n=62). Foi aplicado inquérito telefónico com 7 questões de escolha múltipla. Obtiveram-se 54 respostas e os resultados foram tratados estatisticamente. Verificou-se espasticidade de etiologia cerebral em 100%, com predomínio dos quadros de hemiparésia (81,5%). Os objectivos dos doentes/cuidadores eram: diminuição da espasticidade (70,4%), poder andar melhor (50%) e diminuição da dor (35,2%). Houve satisfação com o tratamento em 90,8%, predominância de efeitos loco-regionais (87%) e muito poucos efeitos indesejados (5,7 %). Foi dada grande relevância a este tratamento no processo de reabilitação (98,1%), traduzindo-se numa motivação para a sua repetição em 96,3%. Comparativamente com estudo previamente realizado, é estatísticamente significativa a diferença encontrada nos objectivos que motivaram o início do tratamento, que anteriormente incidiam na melhoria da postura e na facilitação da vida diária, para além do controlo da espasticidade. A toxina botulínica continua a ser reconhecida, pelos doentes/cuidadores, como uma terapêutica eficaz, segura e muito importante no processo de reabilitação.Sociedade Portuguesa de Medicina Física e de Reabilitação2013-03-09T00:00:00Zjournal articlejournal articleinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://doi.org/10.25759/spmfr.55oai:ojs.spmfrjournal.org:article/55Revista da Sociedade Portuguesa de Medicina Física e de Reabilitação; v. 17, n. 1 (2009): Ano 17; 21-250872-9204reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://spmfrjournal.org/index.php/spmfr/article/view/55https://doi.org/10.25759/spmfr.55https://spmfrjournal.org/index.php/spmfr/article/view/55/60Gouveia, Suzana; Interna de MFR do Hospital de Santa Maria, Lisboa, PortugalAfonso, Carla; Interna de MFR do Centro de Medicina de Reabilitação de Alcoitão, PortugalJacinto, Jorge; Assistente Hospitalar de MFR do Centro de Medicina de Reabilitação de Alcoitão, Portugalinfo:eu-repo/semantics/openAccess2022-09-20T15:28:42Zoai:ojs.spmfrjournal.org:article/55Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:51:17.377845Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Botulinum toxin type A (BTA) impact in Rehabilitation - patient perspective in a medium and long term
Impacto da Toxina Botulínica tipo A na Reabilitação - perspectiva do doente / cuidador a médio e longo prazo
title Botulinum toxin type A (BTA) impact in Rehabilitation - patient perspective in a medium and long term
spellingShingle Botulinum toxin type A (BTA) impact in Rehabilitation - patient perspective in a medium and long term
Gouveia, Suzana; Interna de MFR do Hospital de Santa Maria, Lisboa, Portugal
title_short Botulinum toxin type A (BTA) impact in Rehabilitation - patient perspective in a medium and long term
title_full Botulinum toxin type A (BTA) impact in Rehabilitation - patient perspective in a medium and long term
title_fullStr Botulinum toxin type A (BTA) impact in Rehabilitation - patient perspective in a medium and long term
title_full_unstemmed Botulinum toxin type A (BTA) impact in Rehabilitation - patient perspective in a medium and long term
title_sort Botulinum toxin type A (BTA) impact in Rehabilitation - patient perspective in a medium and long term
author Gouveia, Suzana; Interna de MFR do Hospital de Santa Maria, Lisboa, Portugal
author_facet Gouveia, Suzana; Interna de MFR do Hospital de Santa Maria, Lisboa, Portugal
Afonso, Carla; Interna de MFR do Centro de Medicina de Reabilitação de Alcoitão, Portugal
Jacinto, Jorge; Assistente Hospitalar de MFR do Centro de Medicina de Reabilitação de Alcoitão, Portugal
author_role author
author2 Afonso, Carla; Interna de MFR do Centro de Medicina de Reabilitação de Alcoitão, Portugal
Jacinto, Jorge; Assistente Hospitalar de MFR do Centro de Medicina de Reabilitação de Alcoitão, Portugal
author2_role author
author
dc.contributor.author.fl_str_mv Gouveia, Suzana; Interna de MFR do Hospital de Santa Maria, Lisboa, Portugal
Afonso, Carla; Interna de MFR do Centro de Medicina de Reabilitação de Alcoitão, Portugal
Jacinto, Jorge; Assistente Hospitalar de MFR do Centro de Medicina de Reabilitação de Alcoitão, Portugal
description Botulinum toxin type A (BTA) has been used in our institution since 2001 in a growing number of patients, which lead to the creation of a specific spasticity treatment clinic. We have 370 patients up to October 2007, which account for a total of 731 treatment sessions. We aimed to evaluate the impact of this treatment on the perspective of the patients treated during 2006, and to make a comparative analysis of the results obtained with those of a previous study that we published in 2004. We selected the patients treated in 2006, who had started treatment with BTA for more than 1 year and had had since more than 1 treatment session (n=62). We made a telephone enquiry, consisting of 7 multiple choice questions, and we obtained 54 answers to the hole enquiry. The results were statistically analysed. We found that spasticity was of cerebral aetiology in 100% of cases , and hemiparesis was the most frequent clinical situation (81,5%). The patients’/carers’ aims were: to reduce spasticity (70,4%), to be able to walk better (50%), and to reduce pain (35,2%). The result was satisfying in 90,8% of cases, the local and regional effects predominated (87%) and side effects were very scarse (5,7%). This treatment was considered very relevant for the rehabilitation process (98,1%), which translated in clear motivation for continuing with the treatment in 96,3% of cases. In comparison with the previous study from 2003, there is a statistically significant difference concerning the aims for starting the treatment, which used to focus more on improving posture and facilitate activities of daily living, apart from controlling spasticity. BTA continues to be recognized by patients/carers as an effective, safe and very relevant treatment within the rehabilitation process.
publishDate 2013
dc.date.none.fl_str_mv 2013-03-09T00:00:00Z
dc.type.driver.fl_str_mv journal article
journal article
info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.25759/spmfr.55
oai:ojs.spmfrjournal.org:article/55
url https://doi.org/10.25759/spmfr.55
identifier_str_mv oai:ojs.spmfrjournal.org:article/55
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://spmfrjournal.org/index.php/spmfr/article/view/55
https://doi.org/10.25759/spmfr.55
https://spmfrjournal.org/index.php/spmfr/article/view/55/60
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Medicina Física e de Reabilitação
publisher.none.fl_str_mv Sociedade Portuguesa de Medicina Física e de Reabilitação
dc.source.none.fl_str_mv Revista da Sociedade Portuguesa de Medicina Física e de Reabilitação; v. 17, n. 1 (2009): Ano 17; 21-25
0872-9204
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130376420982784